The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted 6-4 that a clinical trial failed to prove the drug is effective in patients with ALS.
The FDA is not required to follow the committee’s recommendations and is expected to make a final decision on the drug’s approval status by June 29.
Editor’s note: This article was updated March 31 at 5:24 p.m.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
